Clinical management of Her2+ breast cancers includes Her2-targeted monoclonal antibody (mAb) trastuzumab combined with chemotherapy, followed by, or lately in combination with, the newer generation of Her2-targeted mAb pertuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.